JAZZ Stock: Price, Earnings History and SEC Filings
Jazz Pharmaceuticals plc (JAZZ) last traded at $215.98, up 3.92% on the latest session and down 6.7% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $4.89 against an analyst estimate of $5.06, a miss of 3.4%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
JAZZ earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 3, 2026 | $4.89 | $5.06 | -3.36% |
| Mar 2026 | May 5, 2026 | $5.46 | $3.82 | +42.93% |
| Dec 2025 | Feb 24, 2026 | $5.76 | $5.65 | +1.95% |
| Sep 2025 | Nov 5, 2025 | $6.99 | $4.80 | +45.63% |
JAZZ beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
How JAZZ reacts to earnings
Across its last 8 earnings releases, JAZZ moved 5.6% on average the next session, in either direction. It rose after 5 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-10-26 | After close | +0.53% |
| 2026-08-03 | After close | +3.99% |
| 2026-05-05 | After close | +7.68% |
| 2026-02-24 | After close | +13.23% |
| 2026-01-12 | Before open | +1.58% |
| 2025-11-05 | After close | -2.31% |
| 2025-08-05 | After close | -6.42% |
| 2025-05-06 | After close | -8.75% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
JAZZ financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $4.3B | -$356M | $1.3B | -8.3% | $-5.84 |
| 2024 | $4.1B | $560M | $1.4B | 13.8% | $8.65 |
| 2023 | $3.8B | $415M | $1.1B | 10.8% | $6.10 |
| 2022 | $3.7B | -$224M | $1.2B | -6.1% | $-3.58 |
| 2021 | $3.1B | -$330M | $751M | -10.7% | $-5.52 |
| 2020 | $2.4B | $239M | $885M | 10.1% | $4.22 |
| 2019 | $2.2B | $523M | $736M | 24.2% | $9.09 |
| 2018 | $1.9B | $447M | $779M | 23.6% | $7.30 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for JAZZ
- 8-K · Oct 26, 2026Results of operations
- 8-K · Oct 9, 2026Officer or director change
- 8-K · Sep 23, 2026Material agreement, New financial obligation, Financial statements and exhibits
- 8-K · Sep 15, 2026Regulation FD disclosure
- 8-K · Aug 31, 2026Material agreement, New financial obligation, Unregistered share sale
- 8-K · Aug 25, 2026Other events
- 8-K · Aug 10, 2026Material agreement, Financial statements and exhibits
- 8-K · Aug 10, 2026Regulation FD disclosure, Financial statements and exhibits
- 10-Q · Aug 3, 2026
- 8-K · Aug 3, 2026Results of operations, Financial statements and exhibits
Insider filing activity
JAZZ insiders filed 30 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
JAZZ news
- What to expect from Jazz Pharmaceuticals’s (JAZZ) Q3 earningsNov 1, 2026 · finance.yahoo.com
- 3 Biotech Stocks With Upside Of Up To 80%Oct 31, 2026 · finance.yahoo.com
- With Setara, the team behind Actio opens its second actOct 30, 2026 · biopharmadive.com
- Setara Biosciences Announces $90 Million Series A Financing to Advance Precision Medicines for Rare Genetic Diseases and Related Expansion IndicationsOct 30, 2026 · finance.yahoo.com
- Where Will Jazz Pharmaceuticals Be in 5 Years? Oncology Is Becoming Its Growth EngineOct 27, 2026 · fool.com
- Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseOct 27, 2026 · finance.yahoo.com
- Analysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out forOct 26, 2026 · finance.yahoo.com
- Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026Oct 23, 2026 · finance.yahoo.com
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc (JAZZ) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in Ireland. Its fiscal year ends in December.